XBIO 8-K: SEC filing
Xenetic Biosciences
Filed with the SEC on · accession 0001683168-26-008650
XBIO filed a 8-K (current report) with the SEC on Nov 13, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Xenetic Biosciences issued a press release announcing its financial results for the three months ended September 30, 2026, along with strategic business updates, including progress on a proposed share exchange transaction with Santersus AG and its DNase technology programs.
Key details
✦ Ask GOAX AI about this filing — what it means for XBIO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for XBIO?
Click hereFrequently asked questions
What did XBIO file with the SEC on Nov 13, 2026?
XBIO filed a 8-K (SEC filing). Xenetic Biosciences issued a press release announcing its financial results for the three months ended September 30, 2026, along with strategic business updates, including progress on a proposed share exchange transaction with Santersus AG and its DNase technology programs.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other XBIO SEC filings
Get alerts when XBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days